Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 85.81M | 74.38M | 71.54M | 60.12M | 60.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.81M | 74.38M | 71.54M | 60.12M | 60.10M |
| Cost of Revenue | 10.95M | 11.00M | 11.90M | 8.73M | 9.48M |
| Gross Profit | 74.86M | 63.38M | 59.64M | 51.39M | 50.62M |
| SG&A Expenses | 47.50M | 46.46M | 44.39M | 44.02M | 40.14M |
| Depreciation & Amortization | 2.71M | 2.71M | 2.71M | 2.71M | 2.71M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.03M | 67.65M | 67.06M | 63.21M | 58.42M |
| Operating Income | 16.77M | 6.73M | 4.48M | -3.09M | 1.68M |
| Income Before Tax | 11.08M | 621.00K | -1.93M | -9.22M | -5.11M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | 11.08M | 621.00K | -1.93M | -9.22M | -5.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.08M | 621.00K | -1.93M | -9.22M | -5.11M |
| EBIT | 16.77M | 6.73M | 4.48M | -3.09M | 1.68M |
| EBITDA | 19.82M | 9.78M | 7.52M | -65.00K | 4.70M |
| EPS Basic | 0.07 | 0.00 | -0.01 | -0.06 | -0.03 |
| Normalized Basic EPS | 0.04 | 0.00 | -0.01 | -0.04 | -0.02 |
| EPS Diluted | 0.06 | 0.00 | -0.01 | -0.06 | -0.03 |
| Normalized Diluted EPS | 0.04 | 0.00 | -0.01 | -0.04 | -0.02 |
| Average Basic Shares Outstanding | 165.96M | 163.65M | 159.46M | 152.45M | 149.09M |
| Average Diluted Shares Outstanding | 180.07M | 177.62M | 159.46M | 152.45M | 149.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |